Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
| Status: | Completed |
|---|---|
| Conditions: | Skin Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/14/2017 |
| Start Date: | November 15, 2004 |
| End Date: | May 19, 2006 |
A Phase II Study of IL-18 in Melanoma Patients
This Phase II study is designed to evaluate the anti-tumor activity of three dose groups of
SB-485232 (0.01, 0.1, and 1.0 mg/kg/day) administered intravenously as a single agent in
subjects with previously untreated metastatic melanoma.
SB-485232 (0.01, 0.1, and 1.0 mg/kg/day) administered intravenously as a single agent in
subjects with previously untreated metastatic melanoma.
Inclusion criteria:
- Patients must have melanoma that has spread beyond the original location and has not
yet been treated.
- Tissue from the spreading melanoma should have been tested to confirm it is melanoma.
Exclusion criteria:
- Patients having hepatitis or HIV infection.
- Taking corticosteroids.
- Patients with the primary site being occular melanoma or patients with melanoma of the
brain.
We found this trial at
13
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials